J Brooks1, G A Baker, A P Aldenkamp. 1. The Walton Centre for Neurology and Neurosurgery, Lower Lane, Fazakerley, L9 7LJ, Liverpool, UK.
Abstract
PURPOSE: To provide further evidence of the reliability and validity of the ABNAS as a measure of patient-perceived cognitive side effects of antiepileptic drug treatment. METHODS: The measure was developed specifically to assess patient-perceived cognitive side effects of antiepileptic drug treatment. Evidence of its reliability and validity has been previously documented and this evidence has been further extended by administration of a battery of 400 questionnaires to two groups (200 people with epilepsy, PWE; and 200 controls who do not have epilepsy). The questionnaire packs consisted of the ABNAS, HADS, the everyday memory questionnaire, and the Adverse Events Profile. Data were analysed using MAP-R and SPSS. RESULTS: Further evidence of the psychometric properties of the scale demonstrated that it had excellent reliability (Cronbach's alpha=0.96) and good face, congruent, content and construct validity. The sensitivity of the instrument was demonstrated through analysis of floor and ceiling levels. CONCLUSIONS: The ABNAS is a reliable, tool for the detection of cognitive impairments associated with epilepsy and its treatment. We have provided further evidence of its criterion validity. This measure has the potential to be a useful tool for both clinical practice and clinical trials.
PURPOSE: To provide further evidence of the reliability and validity of the ABNAS as a measure of patient-perceived cognitive side effects of antiepileptic drug treatment. METHODS: The measure was developed specifically to assess patient-perceived cognitive side effects of antiepileptic drug treatment. Evidence of its reliability and validity has been previously documented and this evidence has been further extended by administration of a battery of 400 questionnaires to two groups (200 people with epilepsy, PWE; and 200 controls who do not have epilepsy). The questionnaire packs consisted of the ABNAS, HADS, the everyday memory questionnaire, and the Adverse Events Profile. Data were analysed using MAP-R and SPSS. RESULTS: Further evidence of the psychometric properties of the scale demonstrated that it had excellent reliability (Cronbach's alpha=0.96) and good face, congruent, content and construct validity. The sensitivity of the instrument was demonstrated through analysis of floor and ceiling levels. CONCLUSIONS: The ABNAS is a reliable, tool for the detection of cognitive impairments associated with epilepsy and its treatment. We have provided further evidence of its criterion validity. This measure has the potential to be a useful tool for both clinical practice and clinical trials.
Authors: Fiona McGill; Michael J Griffiths; Laura J Bonnett; Anna Maria Geretti; Benedict D Michael; Nicholas J Beeching; David McKee; Paula Scarlett; Ian J Hart; Kenneth J Mutton; Agam Jung; Guleed Adan; Alison Gummery; Wan Aliaa Wan Sulaiman; Katherine Ennis; Antony P Martin; Alan Haycox; Alastair Miller; Tom Solomon Journal: Lancet Infect Dis Date: 2018-06-29 Impact factor: 25.071
Authors: Christophe de Bézenac; Marta Garcia-Finana; Gus Baker; Perry Moore; Nicola Leek; Rajiv Mohanraj; Leonardo Bonilha; Mark Richardson; Anthony Guy Marson; Simon Keller Journal: BMJ Open Date: 2019-10-16 Impact factor: 2.692
Authors: Lara Harris; Julia Griem; Alison Gummery; Laura Marsh; Sylviane Defres; Maneesh Bhojak; Kumar Das; Ava Easton; Tom Solomon; Michael Kopelman Journal: PLoS One Date: 2020-03-25 Impact factor: 3.240